Edition:
United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

2.33SEK
18 Aug 2017
Change (% chg)

-0.03kr (-1.27%)
Prev Close
2.36kr
Open
2.30kr
Day's High
2.39kr
Day's Low
2.27kr
Volume
380,745
Avg. Vol
565,097
52-wk High
3.53kr
52-wk Low
1.77kr

BINV.ST

Chart for BINV.ST

About

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403,... (more)
No analyst recommendations are available for BINV.ST.

Overall

Beta: 0.74
Market Cap(Mil.): kr709.94
Shares Outstanding(Mil.): 304.70
Dividend: --
Yield (%): --

Financials

  BINV.ST Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -0.28 -- --
ROI: -41.10 2.87 14.88
ROE: -41.10 5.20 16.12

BRIEF-Bioinvent Q2 net loss decreases yr/yr

* Q2 earnings after tax: SEK -23 (-27) million. Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jul 26 2017

BRIEF-Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

* Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

Jul 10 2017

BRIEF-Bioinvent and Thrombogenics amend monoclonal antibody development agreement

* BIOINVENT AND THROMBOGENICS AMENDING LONG-STANDING MONOCLONAL ANTIBODY DEVELOPMENT AGREEMENT

Jul 10 2017

BRIEF-BioInvent and Thrombogenics amend monoclonal antibody development agreement

* Bioinvent and Thrombogenics amending long-standing monoclonal antibody development agreement Source text for Eikon: Further company coverage:

Jul 10 2017

BRIEF-BioInvent swings to net loss in Q1

* Q1 earnings after tax SEK -22 (0.3) million Source text for Eikon: Further company coverage: (Stockholm Newsroom)

May 17 2017

Earnings vs. Estimates